Danaher (NYSE:DHR) Issues FY 2026 Earnings Guidance

Danaher (NYSE:DHR) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 8.450-8.600 for the period, compared to the consensus earnings per share estimate of 8.480. The company issued revenue guidance of -.

Danaher Price Performance

DHR traded down $0.76 during trading on Friday, reaching $195.41. The stock had a trading volume of 1,557,659 shares, compared to its average volume of 4,659,237. Danaher has a one year low of $160.93 and a one year high of $242.80. The stock has a market cap of $137.37 billion, a PE ratio of 34.72, a PEG ratio of 2.45 and a beta of 0.79. The business has a 50-day moving average of $187.90 and a 200-day moving average of $195.66. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 21st. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.77 earnings per share. As a group, equities research analysts anticipate that Danaher will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio is currently 28.42%.

Analyst Ratings Changes

DHR has been the subject of a number of research reports. Guggenheim reduced their price objective on Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. JPMorgan Chase & Co. decreased their target price on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Piper Sandler started coverage on Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 price objective for the company. Morgan Stanley cut their target price on Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, April 22nd. Finally, DZ Bank initiated coverage on shares of Danaher in a report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

Institutional Investors Weigh In On Danaher

Several large investors have recently added to or reduced their stakes in DHR. JPL Wealth Management LLC purchased a new stake in shares of Danaher in the 3rd quarter worth about $25,000. WFA of San Diego LLC purchased a new position in Danaher during the second quarter worth approximately $26,000. Transamerica Financial Advisors LLC grew its stake in shares of Danaher by 216.3% during the 4th quarter. Transamerica Financial Advisors LLC now owns 155 shares of the conglomerate’s stock valued at $36,000 after buying an additional 106 shares during the period. Birchwood Financial Partners Inc. acquired a new stake in shares of Danaher during the 4th quarter worth $41,000. Finally, Quattro Advisors LLC acquired a new position in Danaher in the fourth quarter valued at $52,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.